Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Cagrilintide
AM833, CagriSema (in combination with semaglutide)
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Being developed both standalone and in combination with semaglutide (CagriSema) — a combination showing weight loss exceeding 22% in Phase 3 trials, potentially the next step beyond tirzepatide.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Activates amylin receptors (CALCR/RAMP) in the brain, particularly in the area postrema and hypothalamus, reducing appetite through a pathway distinct from GLP-1. The combination with semaglutide targets two separate appetite-regulating systems simultaneously, producing additive weight loss beyond either agent alone.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- GI side effects (nausea, vomiting) — similar to GLP-1 class
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Long-term effects unknown
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
Currently in Phase 3 trials as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg). Phase 3 REDEFINE 1 trial showed ~22.7% weight loss at 68 weeks. Potential FDA submission 2026-2027. Represents the next generation beyond tirzepatide in the weight management pipeline.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.